Terms: = Sarcomas AND BAP1, DKFZp686N04275, 8314, ENSG00000163930, Q92560, KIAA0272, hucep-6, HUCEP-13, FLJ37180, FLJ35406 AND Prognosis
5 results:
1. Characterizing the distribution of alterations in mesothelioma and their correlation to morphology.
Chen-Yost HI; Tjota MY; Gao G; Mitchell O; Kindler H; Segal J; Husain AN; Mueller J; Schulte JJ
Am J Clin Pathol; 2023 Sep; 160(3):238-246. PubMed ID: 37141416
[TBL] [Abstract] [Full Text] [Related]
2. [Expression and clinical significance of SETD2 in maligant pleural mesothelioma].
Yu M; Yu M; Zhu LJ; Yuan XY; Zhang X
Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2021 Feb; 39(2):91-98. PubMed ID: 33691361
[No Abstract] [Full Text] [Related]
3. Intracranial angiomatoid fibrous histiocytoma with rhabdoid features: a mimic of rhabdoid meningioma.
Vizcaino MA; Giannini C; Chang HT; Kipp BR; Fritchie K; Vaubel R
Brain Tumor Pathol; 2021 Apr; 38(2):138-144. PubMed ID: 33432531
[TBL] [Abstract] [Full Text] [Related]
4. Interobserver variation in the assessment of the sarcomatoid and transitional components in biphasic mesotheliomas.
Dacic S; Le Stang N; Husain A; Weynand B; Beasley MB; Butnor K; Chapel D; Gibbs A; Klebe S; Lantuejoul S; Roden AC; Roggli V; Tazelaar H; Vignaud JM; Galateau-Sallé F
Mod Pathol; 2020 Feb; 33(2):255-262. PubMed ID: 31273316
[TBL] [Abstract] [Full Text] [Related]
5. The landscape of targeted therapies for cholangiocarcinoma: current status and emerging targets.
Chong DQ; Zhu AX
Oncotarget; 2016 Jul; 7(29):46750-46767. PubMed ID: 27102149
[TBL] [Abstract] [Full Text] [Related]